Chronic granulocytic leukemia in a horse.

A 9-year-old Quarter Horse with weeks of weight loss and poor appetite developed pneumonia and pleuritis and was found to have severe neutropenia, circulating immature granulocytes, progressive anemia and thrombocytopenia, and a bone marrow packed with immature granulocytic cells. Together, these findings indicate chronic granulocytic leukemia, a rare myeloid cancer in horses.

What this case report is about

• A single-horse case description of chronic granulocytic leukemia (CGL), a myeloproliferative neoplasm in which granulocytic precursors proliferate abnormally.
• The report links progressive systemic illness (weight loss, inappetence) and secondary infection (pneumonia/pleuritis) to profound bone marrow dysregulation.

Clinical presentation and timeline

• Duration: 47 days of progressive clinical decline.
• Key signs: weight loss and reduced appetite (inappetence), consistent with chronic systemic disease.
• Complications: clinical pleuritis and pneumonia, indicating significant susceptibility to infection.

Major laboratory and fluid-analysis findings

• Peripheral blood:
  • Persistent neutropenia across the entire observation period, indicating impaired innate immunity.
  • Circulating abnormal immature granulocytes with few blast cells, suggesting a chronic myeloid process with left shift but not an acute blast crisis.
  • Progressive anemia and thrombocytopenia, consistent with bone marrow failure/ineffective hematopoiesis and marrow crowding by neoplastic cells.
• Pleural fluid:
  • Leukocytosis and elevated protein content, supporting an exudative inflammatory effusion consistent with pneumonia/pleuritis.

Bone marrow findings and their interpretation

• Granulocytic series:
  • Marked predominance of immature granulocytic precursors with very few mature neutrophils, indicating a maturation arrest within the myeloid lineage.
  • This pattern supports a clonal myeloproliferative disorder rather than a purely reactive left shift from infection.
• Erythroid series:
  • Marked megaloblastic transformation of erythroid precursors, reflecting abnormal DNA synthesis and ineffective erythropoiesis.
  • Clinically manifests as progressive anemia despite an active marrow, typical of marrow dysplasia associated with leukemia.

Why the diagnosis is chronic granulocytic leukemia

• Peripheral smear features:
  • Predominance of immature granulocytes with low blast percentage aligns with a chronic granulocytic/myelogenous process rather than acute leukemia (which typically shows high blast counts).
• Marrow architecture:
  • Myeloid hyperplasia with maturation arrest is characteristic of CGL and not expected in simple inflammatory reactions.
• Global cytopenias:
  • Concurrent anemia and thrombocytopenia suggest marrow replacement/dysfunction by a neoplastic clone, not explained by infection alone.

Differential diagnoses considered and how they are excluded

• Severe bacterial infection with a leukemoid reaction:
  • Might cause left shift, but typically with neutrophilia, not persistent neutropenia and marrow maturation arrest.
• Myelodysplastic syndrome:
  • Can cause dysplasia and cytopenias; however, the dominant granulocytic proliferation with circulating immature granulocytes favors CGL.
• Acute myeloid leukemia:
  • Usually features high circulating blasts; here, blasts are low, supporting a chronic rather than acute phenotype.
• Aplastic/hypoplastic marrow or drug-induced suppression:
  • Contradicted by the hypercellular marrow with excess immature myeloid cells.

Pathophysiology linking the findings

• Neoplastic myeloid clone:
  • Overproduction of immature granulocytic cells crowds the marrow and disrupts normal maturation, reducing output of functional neutrophils, red cells, and platelets.
• Immunosuppression and infection:
  • Severe neutropenia predisposes to bacterial pneumonia and pleuritis; pleural fluid exudate reflects active infection/inflammation despite poor systemic neutrophil reserves.
• Ineffective erythropoiesis and thrombopoiesis:
  • Megaloblastic erythroid changes and marrow crowding cause progressive anemia; reduced megakaryocytic function leads to thrombocytopenia.

Clinical implications and expected course

• Rarity in equids:
  • CGL is uncommon in horses; recognition relies on integrating blood counts, smear review, and bone marrow examination.
• Prognosis:
  • Generally guarded to poor due to marrow failure and infection risk, particularly with persistent neutropenia.
• Management considerations (contextual, not specified in the abstract):
  • Supportive care: broad-spectrum antimicrobials for pneumonia/pleuritis, anti-inflammatories, fluid and nutritional support.
  • Hematologic support: cautious use of transfusions if anemia or thrombocytopenia are severe.
  • Definitive therapy: chemotherapy protocols for equine myeloid neoplasms are not standardized and outcomes are variable.

Significance and limitations of the report

• Significance:
  • Highlights that equine CGL can present with neutropenia (not only leukocytosis) and severe marrow dysplasia, leading to life-threatening infections.
• Limitations:
  • Single case; no cytogenetic or molecular characterization reported, which limits mechanistic insights and comparability across cases.
  • Lack of treatment and outcome details in the abstract precludes assessment of therapeutic response.

Key takeaways for practitioners

• Persistently abnormal counts (neutropenia with circulating immature granulocytes) plus progressive bi- or pancytopenia warrant bone marrow evaluation in horses with chronic illness.
• Bone marrow showing granulocytic maturation arrest with megaloblastic erythroid changes supports a diagnosis of chronic granulocytic leukemia.
• Expect high risk of secondary infections; prioritize aggressive supportive and antimicrobial care while pursuing definitive diagnosis and discussing prognosis.